ALMDP.PA stock Medesis Pharma EURONEXT trading €0.35 intraday 13 Mar 2026: watch oversold bounce to €0.60

ALMDP.PA stock, Medesis Pharma S.A. on EURONEXT, trades at €0.35 intraday on 13 Mar 2026 with an unusual volume spike of 149,072 shares. The price sits above the day low €0.34 and below the 50-day average €0.37, setting a classic oversold bounce scenario for short-term traders. We examine liquidity, fundamentals, technical triggers, and a model price target to frame risk and reward for the oversold bounce trade.

ALMDP.PA stock intraday price action

Medesis Pharma (ALMDP.PA) opened at €0.34 and is trading intraday between €0.34 and €0.40 on EURONEXT in Europe. Volume today is 149,072, well above the average volume of 15,909, giving the move higher short-term significance.

The intraday range and volume suggest active repositioning after steep multi‑month weakness. The stock sits near its year low €0.30, which often attracts mean‑reversion interest in micro‑caps.

ALMDP.PA stock valuation and fundamentals

Medesis Pharma is a clinical‑stage biotechnology company with a market cap of €1,801,314.00 and 5,146,610 shares outstanding. Recent trailing metrics show EPS -0.59 and a negative PE ratio -0.59, reflecting ongoing R&D losses and limited revenue.

Key ratios: price/sales 6.00, current ratio 0.38, and debt to market cap 0.67. These figures underline a high-risk development profile and tight short‑term liquidity.

Sector context and ALMDP.PA stock opportunities

Medesis operates in the Healthcare/Biotechnology sector, which shows muted performance year to date and a one‑year change near -0.15%. Biotech headlines and sector rotations influence micro‑cap names like ALMDP.PA more than large caps.

An oversold bounce can be stronger when sector momentum improves. Monitor sector flows and any Medesis news on NanoLithium or clinical updates for directional conviction.

Technical setup, liquidity and trading signals

Price sits below the 200‑day average €0.50 and just under the 50‑day average €0.37, signalling a downtrend with a possible short squeeze or bounce target at the 50‑day moving average. Relative volume is high at 9.37 times average, improving execution for active traders.

Short‑term support is €0.30 and resistance cluster runs €0.37–€0.40. Use tight stops given low free float and rapid intraday swings.

Meyka AI grade and ALMDP.PA stock forecast

Meyka AI rates ALMDP.PA with a score out of 100: 64.99 | Grade: B | Suggestion: HOLD. This grade factors S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a near‑term bounce to €0.60, implying 71.43% upside from €0.35. Forecasts are model‑based projections and not guarantees.

Risks, catalysts and an oversold bounce strategy

Primary risks include cash burn, low current ratio 0.38, negative EPS -0.59, and binary clinical outcomes. News delays or funding announcements can swing the stock sharply.

A disciplined oversold bounce trade: size positions small, target a first profit at €0.50, stop below €0.30, and scale out into resistance. Watch company updates and sector flows for a catalyst confirmation.

Final Thoughts

ALMDP.PA stock currently trades at €0.35 on EURONEXT with heavy intraday volume of 149,072, creating a technical oversold bounce opportunity. Fundamentals remain weak: EPS -0.59, current ratio 0.38, and market cap €1,801,314.00 highlight substantial execution risk. Meyka AI’s model projects a short‑term bounce target of €0.60, an implied upside of 71.43% from the current price, while a conservative interim target is €0.50 near the 200‑day influence zone. Traders should treat this as a high‑volatility micro‑cap play, size positions modestly, and use strict stops below €0.30. Remember, Meyka AI is an AI‑powered market analysis platform; forecasts are model‑based projections and not guarantees. Monitor clinical updates, funding news, and sector flows to validate any rebound

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.